Summary for Tradename: NATRECOR
Clinical Trials for: NATRECOR
Natrecor for Pulmonary Hypertension in Lung Transplants
Status: Completed Condition: Pulmonary Hypertension
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Status: Completed Condition: Congestive Heart Failure
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Status: Terminated Condition: Congestive Heart Failure; Cardiac Transplantation; Renal Insufficiency; Renal Failure
A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
Status: Completed Condition: Cardiomyopathies; Heart Failure, Congestive; Dyspnea, Paroxysma
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status: Withdrawn Condition: Heart Failure, Congestive; Dyspnea; Pulmonary Edema
Natrecor in Pulmonary Hypertension
Status: Terminated Condition: Pulmonary Hypertension; Cancer; Lung Disease; Cardiothoracic Surgery
Nesiritide and Vo2 Max in Heart Failure Patients
Status: Completed Condition: Heart Failure
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
Status: Completed Condition: Heart Failure, Congestive
Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Status: Terminated Condition: Heart Failure; Cardiovascular Disease; Acute Heart Failure; Diastolic Heart Failure; Congestive Heart Failure; Heart Disease
Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
Status: Terminated Condition: Heart Defects, Congenital
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|FOR SOLUTION;INTRAVENOUS||020920||Aug 10, 2001||RX||Yes||5,114,923||<disabled>||Y||Y||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639